2026-526859-54-00招募中1 期
A Randomised, Placebo‑Controlled Trial to Assess Effect of IMU‑838 on QT/QTc
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Immunic AG
- 入组人数
- 20
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Michael Panzara
Scientific
Immunic AG
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
A Randomized Controlled Trial to Evaluate the Effect of a Senior-targeted SNS "Oshiruco" on Social Frailty among Older Adultsfrailty
social frailtyfrailty social frailtyjRCT1022250034100
尚未招募
不适用
Phase 3 Study of Adjuvant Intismeran With or Without MK-3475A in High-Risk Stage I NSCLCNon-Small Cell Lung CancerjRCT202126002854
招募中
不适用
A Randomized Controlled Trial to Evaluate the Efficacy of a PHR App for Self-Management Support and a Stapwise Reminder Interventions (STEP-UP trial)HypertensionjRCT1040260027100
招募中
1 期
A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC.ULCERATIVE COLITIS2022-501047-32-00Pfizer Inc.35
已完成
1 期
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Aticaprant (JNJ-67953964)2023-503258-11-00Janssen - Cilag International48